Atypical Parkinsonian Syndromes: A General Neurologists Perspective
Eur J Neurol 25:41-58, Deutschlander, A.B.,et al, 2018
Advances in Progressive Supranuclear Palsy: New Diagnostic Criteria, Biomarkers, and Therapeutic Approaches
Lancet Neurol 16:552-563, Boxer, A.L.,et al, 2017
Degenerative Diseases of the Nervous System, Progressive Supranuclear Palsy
Adams & Victors Principles of Neurology, Chp 39, pg 1096, Ropper, A.H.,et al, 2014
Progressive Supranuclear Palsy: A Current Review
The Neurologist 14:79-88, Lubarsky,M. &Juncos,J.L., 2008
Diffusion-Weighted Imaging Discriminates Progressive Supranuclear Palsy from PD, But Not From the Parkinson Variant of Multiple System Atrophy
Neurol 60:922-927, Seppi,K.,et al, 2003
Zolpidem in Progressive Supranuclear Palsy
NEJM 341:543-544, Daniele,A.,et al, 1999
Pharmacological Therapy in Progressie Supranuclear Palsy
Arch Neurol 55:1099-1102, Kompoliti,K.,et al, 1998
Botulinum Toxin-A Improves the Rigidity of Progressive Supranuclear Palsy
Ann Neurol 35:237-239, Polo,K.B.&Jabbari,B., 1994
Idazoxan Treatment in Progressive Supranuclear Palsy
Neurol 41:986-991, Ghika,J.,et al, 1991
Autologous Adrenal Medullary Transplant in Progressive Supranuclear Palsy
Neurol 39:1066-1068, Koller,W.C.,et al, 1989
Treatment of Progressive Supranuclear Palsy with Tricyclic Antidepressants
Neurol 35:1189-1193, Newman,G.C., 1985
Progressive Supranuclear Palsy:Clinical Features & Response to Treatment in 16 Patients
Ann Neurol 13:273-278, Jackson,J.A.,et al, 1983
Progressive Supranuclear Palsy:Functional Analysis of the Response to Methysergide & Antiparkinsonian Agents
Neurol 31:1507-1518, Rafal,R.D.,et al, 1981